Collaboration of Multidisciplines for Biomarker Testing Implementation Needed for Effective Treatment Decisions in mCRC

While the advent of biomarker testing and targeted therapies has significantly transformed outcomes for patients with metastatic colorectal cancer, it can be challenging for multidisciplinary teams to stay abreast of the latest clinical advances in the face of ever-expanding testing and treatment possibilities. The Association of Community Cancer Centers (ACCC)—in partnership with the American Society for Clinical Pathology (ASCP) and the France Foundation—is committed to ensuring providers are equipped with the knowledge needed to apply guidelines and current research on therapeutic targets for mutations in patients with metastatic colorectal cancer as well as engage patients in shared decision-making regarding biomarker testing and treatment options.

The goal of this initiative is to provide guidance for multidisciplinary care teams on how to develop practical biomarker testing protocols for metastatic colorectal cancer and how this information can support personalized treatment decisions for improved patient outcomes.

This live workshop delivers a combination of interactive formats that allow for continuous assessment of knowledge gaps. Participants will develop a personalized action plan for incorporating new insights and competencies into practice. 

Participants will engage in interactive, small-group activities, including:

• A multidisciplinary molecular-based tumor board panel
• Breakout sessions which shall delve into biomarker testing guidelines, challenges, and treatment selection
• Patient counseling and shared decision making

Learning Objectives

• Apply the latest guideline recommendations regarding biomarker testing in mCRC
• Describe when biomarker testing should be performed, including the process/protocols and the role of the multidisciplinary team
• Explain the need for biomarker testing to guide individualized therapy decisions to their colleagues and patients
• Review targeted therapeutic options for the treatment of mCRC and identify their utilization in appropriate patients
• Describe the role of CRC care team members and explain techniques to increase communication and collaboration
• Formulate a plan for testing-related discussions with patients and encourage participation in treatment planning.

Locations and Dates

Register Now

This activity is jointly provided by The France Foundation, American Society for Clinical Pathology, and Association of Community Cancer Centers.

This activity will award AMA PRA Category 1 Credit(s)™ and nursing contact hours.

For additional CE information, please visit tffevents.com/crc.